DIURETIC RESISTANCE: CAUSES, MECHANISMS, AND POTENTIALS FOR COPING
- Authors: Khamkhoeva MS1, Fomin VV1, Khamkhoeva MS1, Fomin V.V.1
-
Affiliations:
- Issue: No 12 (2010)
- Pages: 19-23
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278499
- ID: 278499
Cite item
Full Text
Abstract
The present article is concerned with causes, development and approaches to the coping of diuretic resistance (DR). DR is common presentation sign in patients with severe diseases, for example, in patients with more extreme degrees of nephrotic syndrome or decompensated chronic heart failure. DR always considerably complicates treatment and often leads to worsening of prognosis. It is clear that solution of this problem requires a multidisciplinary approach - the replacement of diuretic and/or increasing the doses only is often ineffective.
Keywords
References
- Patel BV, Remigio-Baker RA, Thiebaud P, et al. Improved persistence and adherence to diuretic fixed-dose combination therapy compared to diuretic monotherapy. BMC Fam Pract 2008;9:61.
- Chui MA, Deer M, Bennett SJ, et al. Association between adherence to diuretic therapy and health care utilization in patients with heart failure. Pharmacotherapy 2003;23(3):326-32.
- MacFadyen RJ, Gorski JC, Brater DC, et al. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol 2004;57(5):622-31.
- Müller K, Gamba G, Jaquet F, et al. Torasemide vs. furosemide in primary care patients with chronic heart failure NYHA II to IV - efficacy and quality of life. Eur J Heart Fail 2003;5(6):793-801.
- Greenberg A. Diuretic complications. Am J Med Sci 2000;319(1):10-24.
- Hunter DJ, York M, Chaisson CE, et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006;33(7):1341-45.
- Taniguchi A, Kamatani N. Control of renal uric acid excretion and gout. Curr Opin Rheumatol 2008;20(2):192-97.
- Al-Sheikh AAK, van der Heuvel JJMW, Koenderink JB, et al. Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4. Br J Pahrmacol 2008;155:1066-75.
- Lyseng-Williamson KA. Torasemide prolonged release. Drugs 2009;69(10):1363-72.
- Bleich M, Greger R. Mechanism of action of diuretics. Kidney Int 1997;51(Suppl. 59):S11-S15.
- Tesar V, Zima T, Kalousova M. Pathobiochemistry of nephrotic syndrome. Adv Clin Chem 2003;37:173-218.
- Dunn CJ, Fitton A, Brogden RN. Torasemide. An update of its pharmacological properties and therapeutic efficacy. Drugs 1995;49(1):121-42.
- Kim EJ, Lee MG. Pharmacokinetics and pharmacodynamics of intravenous trasemide in mutant Nagase analbuminemic rats. Biopharm. Drug Dispos 2003;24(1):27-35.
- Suki WN. Use of diuretics in chronic renal failure. Kidney Int 1997;51(Suppl. 59):S33-S35.
- Boesken WH, Kult J. High-dose torasemide, given once daily intravenously for one week, in patients with advanced chronic renal failure. Clin Nephrol 1997;48(1):22-28.
- Fliser D, Schroter M, Neubeck M, et al. Coadministration of thiazides increases the efficacy of loop diuretics even in patients with advanced renal failure. Kidney Int 1994;46(2):482-88.
- Gehr TW, Rudy DW, Matzke GR, et al. The pharmacokinetics of intravenous and oral torsemide in patients with chronic renal insufficiency. Clin Pharmacol Ther 1994;56(1):31-38.
- Orth SR, Ritz E. The nephritic syndrome. N Engl J Med 1998;338:1202-11.
- Valentin JP, Qiu C, Muldowney WP, et al. Cellular basis for blunted volume expansion natriuresis in experimental nephrotic syndrome. J Clin Invest 1992;90(4):1302-12.
- Bramham K, Hunt BJ, Goldsmith D. Thrombophilia of nephrotic syndrome in adults. Clin Adv Hematol Oncol 2009;7(6):368-72.
- Dougall HT, McLay J. A comparative review of the adverse effects of calcium antagonists. Drug Saf 1996;15(2):91-106.
Supplementary files
